» Articles » PMID: 2884932

Effect of Sulphasalazine on the Radiological Progression of Rheumatoid Arthritis

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 1987 May 1
PMID 2884932
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

We have investigated the influence of sulphasalazine, a second line antirheumatic drug, on the radiological progression of erosions in rheumatoid arthritis over a two year period in 41 patients. Hand radiograph scores deteriorated significantly over this period, but in a group of 31 patients in whom one year films were also available this deterioration was limited to the first year. This slowing of radiological deterioration was not related to 'normalisation' of the erythrocyte sedimentation rate (ESR). Compared with a 'control' group of 10 patients who had refused offers of second line therapy, sulphasalazine treated patients showed less deterioration over the two year period, and this difference was more marked than in previous studies of gold or penicillamine. No significant change was seen in large joint radiographs in sulphasalazine treated patients over two years, but this probably represents the poor sensitivity of the method of assessment. No significant correlation was seen between changes in inflammatory indices and slowing of radiological deterioration in erosion score. Thus sulphasalazine appears to slow the progression of radiological disease of the hands over the second year of treatment in a representative sample of patients who continue to receive treatment for two years.

Citing Articles

Creative trial design in RA: optimizing patient outcomes.

Buch M, Pavitt S, Parmar M, Emery P Nat Rev Rheumatol. 2013; 9(3):183-94.

PMID: 23381561 DOI: 10.1038/nrrheum.2013.5.


Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.

Schett G, Coates L, Ash Z, Finzel S, Conaghan P Arthritis Res Ther. 2011; 13 Suppl 1:S4.

PMID: 21624183 PMC: 3123965. DOI: 10.1186/1478-6354-13-S1-S4.


Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Nurmohamed M, Dijkmans B Drugs. 2005; 65(5):661-94.

PMID: 15748099 DOI: 10.2165/00003495-200565050-00006.


Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Scott D, Smolen J, Kalden J, van de Putte L, Larsen A, Kvien T Ann Rheum Dis. 2001; 60(10):913-23.

PMID: 11557646 PMC: 1753377. DOI: 10.1136/ard.60.10.913.


Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis.

McInnes I, Porter D, Murphy E, Thomson E, Madhok R, Hunter J Ann Rheum Dis. 1996; 55(5):328-30.

PMID: 8660109 PMC: 1010172. DOI: 10.1136/ard.55.5.328.


References
1.
Larsen A, Dale K, Eek M . Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh). 1977; 18(4):481-91. DOI: 10.1177/028418517701800415. View

2.
MCCONKEY B, Amos R, Durham S, Forster P, Hubball S, Walsh L . Sulphasalazine in rheumatoid arthritis. Br Med J. 1980; 280(6212):442-4. PMC: 1600457. DOI: 10.1136/bmj.280.6212.442. View

3.
Bird H, Dixon J, Pickup M, Rhind V, Lowe J, Lee M . A biochemical assessment of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1982; 9(1):36-45. View

4.
GOFTON J, OBrien W . Effects of auranofin on the radiological progression of joint erosion in rheumatoid arthritis. J Rheumatol Suppl. 1982; 8:169-72. View

5.
Neumann V, Grindulis K, Hubball S, MCCONKEY B, WRIGHT V . Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J (Clin Res Ed). 1983; 287(6399):1099-102. PMC: 1549360. DOI: 10.1136/bmj.287.6399.1099. View